![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » SKYEPHARMA ANNOUNCES FORADIL(R) CERTIHALER(TM) LAUNCHED IN GERMANY
SKYEPHARMA ANNOUNCES FORADIL(R) CERTIHALER(TM) LAUNCHED IN GERMANY
September 7, 2005
SkyePharma PLC (Nasdaq: SKYE; LSE: SKP) announces today that its partner Novartis Pharma AG (Novartis) has launched FORADIL(R) CERTIHALER(TM) (formoterol fumarate inhalation powder) on the German market for the treatment of asthma and chronic obstructive pulmonary disease (COPD). The German pharmaceutical regulatory authority approved FORADIL(R) CERTIHALER(TM) in June. FORADIL(R) CERTIHALER(TM) is a trademark of Novartis.
PR Newswire (http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=104&STORY=/www/story/09-07-2005/0004101498&EDATE=)
KEYWORDS Daily International Pharma Alert
Upcoming Events
-
21Oct